Navigation Links
Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint

consin, said “The correlation between plasma levels of drug and response rates found in this trial is very exciting. The results of this study show that when psychotically depressed patients achieve a threshold concentration of CORLUX in their system, a rapid and sustained clinical response is likely. This is a strong demonstration of a drug effect in an illness that is potentially devastating and difficult to treat.” Dr. Kalin is a member of Corcept’s Scientific Advisory Board.

Next Phase 3 Clinical Trial Being Planned

Robert L. Roe, M.D., Corcept’s President said, “We believe that the confirmation of a drug concentration threshold for efficacy as well as other observations from Study 06 and the company’s two recently completed Phase 3 clinical trials will serve as a strong basis for the company’s next Phase 3 study. In the upcoming trial which is planned to commence later in 2007, we expect to use a dose level of 1200 mg once per day for seven days because, in Study 06, 80% of the patients achieved a drug plasma level sufficient for a strong clinical response at that dose. In our initial review of a summary of the safety data, we have seen no difference between any of the dose levels used in Study 06. We believe that this change in dose as well as other modifications to the protocol should allow us to definitively demonstrate the efficacy of CORLUX in the treatment of the psychotic features of PMD.”

About Study 06

Study 06 was a randomized, double-blind, placebo-controlled study in which 443 patients were enrolled at 45 sites in the United States and Europe. The primary endpoint, a responder analysis, was the proportion of patients with at least a 50 percent improvement in the Brief Psychiatric Rating Scale Positive Symptom Subscale (BPRS PSS) at both Day 7 and Day 56. Specifically, the BPRS is an 18-item rating instrument used to assess psychopathology, and the PSS is a subset of four ite
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that a ... catalogue: North America Aesthetic Lasers and ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North America ... 2020 Summary GlobalData,s new report, "North ... to 2020", provides key market data on the ...
(Date:8/28/2014)... , Aug. 28, 2014 ... report is available in its catalogue: ... 2014-2024 http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html ... – discover technological and commercial prospects What ... delivery market? Visiongain,s brand new report shows ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18
... , , FREEHOLD, N.J. , Feb. 3 ... it has engaged Morgan Joseph & Co. Inc., ... to maximize shareholder value with respect to Speedus Corp,s subsidiary, ... medical software to identify and classify suspected systolic and diastolic ...
... , HOUSTON and DALLAS , ... along with the company,s management, medical staff, and employees, are making multiple ... earthquake in Haiti . , In response to the magnitude ... million homeless, and over 195,000 awaiting medical attention, First Choice owner ...
Cached Medicine Technology:Speedus Engages Morgan Joseph to Evaluate Strategic Alternatives for Zargis Subsidiary 2Speedus Engages Morgan Joseph to Evaluate Strategic Alternatives for Zargis Subsidiary 3First Choice ER to Donate Over $15,000 in Medical Supplies to Haitian Earthquake Victims 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... Nutrition and Pharameuticals. Nutraceuticals is a source of ... ingredients from natural food sources. Nutraceutical ingredients have ... to the human body. Nutraceutical health products include ... fortified foods and more. Although nature is the ...
(Date:8/30/2014)... Acne is a common problem millions of American cope ... than a daily nuisance, for some, it can have a crippling ... even lead to dramatic mood swings and depression. , Those ... up their skin. In some cases, that can make the problem ... error, those on a quest for clearer skin can now view ...
(Date:8/30/2014)... 30, 2014 Continuing to meet the ... expanding with the addition of a new doctor and ... has provided leading-edge skin care in Grand Rapids since ... , “As a doctor, my passion is making sure ... with Forefront Dermatology, I’m better able to focus on ...
(Date:8/30/2014)... a plant-based medication commonly used to treat gout, ... in reducing potential complications from this type of ... gastrointestinal adverse effects, according to a study published ... released early online to coincide with its presentation ... Common complications after cardiac surgery include postpericardiotomy syndrome ...
(Date:8/30/2014)... August 30, 2014 The federal ... lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific ... four cases selected for one of the proceeding’s ... August 18, 2014, U.S. District Judge Joseph R. ... disagrees with Boston Scientific’s contention that a consolidated ...
Breaking Medicine News(10 mins):Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
... (WASHINGTON, June 4, 2009) The American Society of ... its 2009 Minority Medical Student Award Program (MMSAP), which ... hematology research. Under the program, each award recipient will ... career development mentor, travel stipends to attend the ASH ...
... , MENTOR, Ohio, June 5 Join STERIS Isomedix Services ... critical to success in medical device sterilization ... 23, will provide attendees the opportunity to learn about sterilization ... , In addition to the TechTeam experts from STERIS Isomedix ...
... leader in pain prescription monitoring, has announced the appointment of ... Contracting. Hurley will oversee the company,s contracting activities and ... are thrilled to have Sean on board," said Ancelmo E. ... commitment to provide our payors with both data and tools ...
... the start, expert says , FRIDAY, June 5 (HealthDay News) ... the summer sun, but parents should remember that no tan ... form a tan, you will have ultraviolet radiation damage," Dr. ... Hospital, said in a news release from the northern California ...
... Dad consume has little effect on children,s choices, study ... eating habits don,t seem to influence their children,s food ... suggests. , "We found that the resemblance in dietary ... senior author Dr. Youfa Wang, an associate professor of ...
... Healthcare Informatics as the number 48 healthcare IT company by revenue ... Inc. (Nasdaq: IFLG ), a leading technology ... today announced that the company has been named to ... the fourth time in five years. , , (Logo: ...
Cached Medicine News:Health News:Minority medical students receive support to pursue hematology research 2Health News:Medical Device Sterilization Seminar Offered by STERIS Isomedix Services 2Health News:Medical Device Sterilization Seminar Offered by STERIS Isomedix Services 3Health News:Sean Hurley Joins Ameritox as Vice President for Insurance and Managed Care Contracting 2Health News:Wear Sunscreen for Lifelong Benefits 2Health News:Parental Eating Habits Don't Rub Off on Kids 2Health News:InfoLogix Named as One of the Top 50 Healthcare Information Technology Companies in the World 2Health News:InfoLogix Named as One of the Top 50 Healthcare Information Technology Companies in the World 3
... test device provides clear, reliable ... results can be determined in ... positive results require only 8 ... sample application will dependably and ...
... are available in 14 configurations including the ... Microgenics Antibody Technology, the SureStep™ MDMA (Ecstasy) ... immunoassay targeted to detect MDMA that has ... but no cross-reactivity to any isomer of ...
... are available in 14 configurations including the ... Microgenics Antibody Technology, the SureStep™ MDMA (Ecstasy) ... immunoassay targeted to detect MDMA that has ... but no cross-reactivity to any isomer of ...
... QuickScreen™ multi-panel dip cards offer minimal exposure ... of any conceivable combination of 9 different ... your drug testing program. Just dip the ... timer tells you when to read the ...
Medicine Products: